Search

Your search keyword '"Cervarix (Vaccine)"' showing total 10 results
Start Over Descriptor "Cervarix (Vaccine)" Journal m2 communications
10 results on '"Cervarix (Vaccine)"'

1. Adult and Adolescent Vaccines Market to 2018 - Pharmaceutical giants GSK and Merck are Fighting it Out

Subjects
Merck & Company Inc., Adults, Vaccines, Pharmaceutical industry, General interest, News, opinion and commentary, Cervarix (Vaccine)
Abstract

Mar 07, 2014 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/lb47ph/adult_and) has announced the addition of the 'Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in [...]

Published
2014

2. Regulatory Update - GSK receives positive CHMP opinion for Cervarix(TM) two-dose schedule

Subjects
GlaxoSmithKline PLC, Cervical cancer, Vaccines, Pharmaceutical industry, General interest, News, opinion and commentary, Cervarix (Vaccine)
Abstract

Nov 28, 2013 (M2 PRESSWIRE via COMTEX) -- Today, GlaxoSmithKline plc (GSK) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is recommending marketing authorisation [...]

Published
2013

4. Regulatory update -- GSK announces EU submission for Cervarix[R] two dose schedule

Subjects
Papillomavirus infections -- Drug therapy, Cervical cancer -- Drug therapy, Vaccines, General interest, News, opinion and commentary, European Union, Cervarix (Vaccine)
Abstract

Aug 07, 2013 (M2 PRESSWIRE via COMTEX) -- GlaxoSmithKline (GSK) plc today announced the submission of a regulatory application in the European Union for a two dosing schedule in 9-14 [...]

Published
2013

6. Adult and Adolescent Vaccines Market to 2018 Report

Subjects
Merck & Company Inc., Adults, Vaccines, Pharmaceutical industry, General interest, News, opinion and commentary, Cervarix (Vaccine)
Abstract

Apr 18, 2013 (M2 PRESSWIRE via COMTEX) -- Research and Markets has announced the addition of the Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage [...]

Published
2013

7. Data published in The Lancet Oncology support high efficacy previously demonstrated by Cervarix[R] (HPV 16 and 18 vaccine) against precancerous cervical lesions caused by HPV 16 and 18 and also efficacy against certain other cancer-causing HPV types

Subjects
Cancer -- Prevention, Papillomavirus infections -- Drug therapy, Cervical cancer -- Drug therapy, Vaccines, General interest, News, opinion and commentary, Cervarix (Vaccine)
Abstract

Nov 09, 2011 (M2 PRESSWIRE via COMTEX) -- An analysis published today in The Lancet Oncology reinforces previous findings showing that GlaxoSmithKline's Cervarix ® , provided protection against advanced precancerous [...]

Published
2011

9. GlaxoSmithKline gets US approval for Cervarix cervical cancer vaccine

Subjects
GlaxoSmithKline PLC, Papillomavirus infections -- Drug therapy, Cervical cancer -- Drug therapy, Cancer -- Care and treatment, Pharmaceutical industry, Cancer vaccines, General interest, News, opinion and commentary, Cervarix (Vaccine)
Abstract

Oct 19, 2009 (M2 EQUITYBITES via COMTEX) -- GlaxoSmithKline plc (NYSE:GSK) declared on Friday the receipt of US approval for its cervical cancer vaccine, Cervarix. The US Food and Drug [...]

Published
2009

10. Crown Equity Holdings, Inc.: FDA Approves Cervarix, GlaxoSmithKline's Cervical Cancer Vaccine

Subjects
Cervical cancer -- Drug therapy, Papillomavirus infections -- Drug therapy, Cancer -- Care and treatment, Pharmaceutical industry, Drug approval, Cancer vaccines, General interest, News, opinion and commentary, Cervarix (Vaccine)
Abstract

Las Vegas, Oct 16, 2009 (M2 PRESSWIRE via COMTEX) -- CRWENews.com would like to highlight a stock watch on GlaxoSmithKline (NYSE: GSK - News) announced today October 16, 2009 that [...]

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results